Targeting the dopamine D3 receptor: an overview of drug design strategies

Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia

(2016) Xue Sun et al.   ACTA PHARMACOLOGICA SINICA

Evidence for the heterotetrameric structure of the adenosine A 2A –dopamine D 2 receptor complex

(2016) Verònica Casadó-Anguera et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Allosteric mechanisms within the adenosine A2A–dopamine D2 receptor heterotetramer

(2016) Sergi Ferré et al.   NEUROPHARMACOLOGY

Rotigotine is a potent agonist at dopamine D1receptors as well as at dopamine D2and D3receptors

(2015) Martyn Wood et al.   BRITISH JOURNAL OF PHARMACOLOGY

Molecular imaging of levodopa-induced dyskinesias

(2015) Flavia Niccolini et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling

(2015) Oscar Solís et al.   CEREBRAL CORTEX

Dopamine D3 receptor agonists as pharmacological tools

(2015) S. Kassel et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists

(2015) Cheryse A. Furman et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs

(2015) Emilio Merlo Pich et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The D3 dopamine receptor: From structural interactions to function

(2015) Chiara Fiorentini et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation

(2015) Roberto Maggio et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial

(2015) Gary S. Sachs et al.   JOURNAL OF AFFECTIVE DISORDERS

Analysis of Human Dopamine D3Receptor Quaternary Structure

(2015) Sara Marsango et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges

(2015) Anni Wong et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia

(2015) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Structure–Activity Study of N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a Bitopic Ligand That Acts as a Negative Allosteric Modulator of the Dopamine D2 Receptor

(2015) Jeremy Shonberg et al.   JOURNAL OF MEDICINAL CHEMISTRY

High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice

(2015) Comfort A. Boateng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis

(2015) Thomas M. Keck et al.   JOURNAL OF MEDICINAL CHEMISTRY

Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease

(2015) Kara M Smith et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Identification of novel biomarkers for Parkinson's disease by metabolomic technologies

(2015) Taku Hatano et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum

(2015) Rafael Franco et al.   MOLECULAR NEUROBIOLOGY

Restless legs syndrome—current therapies and management of augmentation

(2015) Claudia Trenkwalder et al.   Nature Reviews Neurology

Dopamine Receptors and Neurodegeneration

(2015) Claudia Rangel-Barajas et al.   Aging and Disease

Lentiviral Vector-Mediated Dopamine D3 Receptor Modulation in the Rat Brain Impairs Alcohol Intake and Ethanol-Induced Conditioned Place Preference

(2014) Amine Bahi et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Dopamine receptors - IUPHAR Review 13

(2014) Jean-Martin Beaulieu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pramipexole Derivatives as Potent and Selective Dopamine D3Receptor Agonists with Improved Human Microsomal Stability

(2014) Jianyong Chen et al.   ChemMedChem

Dopamine D3 receptor alterations in cocaine-dependent humans imaged with [11C](+)PHNO

(2014) David Matuskey et al.   DRUG AND ALCOHOL DEPENDENCE

Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease

(2014) James E. Frampton   DRUGS

Drug safety evaluation of ropinirole prolonged release

(2014) Fabrizio Stocchi et al.   Expert Opinion On Drug Safety

Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease

(2014) Kjell Fuxe et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pharmacological Treatment of Parkinson Disease

(2014) Barbara S. Connolly et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists

(2014) Jianyong Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design, Synthesis, and Structure–Activity Relationship Studies of a Series of [4-(4-Carboxamidobutyl)]-1-arylpiperazines: Insights into Structural Features Contributing to Dopamine D3 versus D2 Receptor Subtype Selectivity

(2014) Subramaniam Ananthan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia

(2014) Daniel Farré et al.   MOLECULAR NEUROBIOLOGY

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

(2014) Peter A. LeWitt   MOVEMENT DISORDERS

Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds

(2014) Claudia Rangel-Barajas et al.   NEUROPHARMACOLOGY

Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone

(2014) Gian Marco Leggio et al.   NEUROPSYCHOPHARMACOLOGY

Dopamine D3 Receptors in the Basolateral Amygdala and the Lateral Habenula Modulate Cue-Induced Reinstatement of Nicotine Seeking

(2014) Maram ATM Khaled et al.   NEUROPSYCHOPHARMACOLOGY

In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism

(2014) David Erritzoe et al.   NEUROPSYCHOPHARMACOLOGY

The novel dopamine D3 receptor antagonist, SR 21502, reduces cocaine conditioned place preference in rats

(2014) P. Hachimine et al.   NEUROSCIENCE LETTERS

Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance

(2014) Richard P. Allen et al.   SLEEP MEDICINE

Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66

(2014) Vivek Kumar et al.   ACS Medicinal Chemistry Letters

Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs

(2014) Thomas J. Moore et al.   JAMA Internal Medicine

Implication of dopamine D3 receptor activation in the reversion of Parkinson’s disease-related motivational deficits

(2014) S Carnicella et al.   Translational Psychiatry

Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development

(2014) Bernard Le Foll et al.   Frontiers in Pharmacology

Complexity of dopamine metabolism

(2013) Johannes Meiser et al.   Cell Communication and Signaling

Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials

(2013) M. Chondrogiorgi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

(2013) Leslie Citrome   Expert Opinion on Drug Metabolism & Toxicology

Dopamine receptor agonists for Parkinson's disease

(2013) Fabio Blandini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dopamine D3 receptor antagonists: a patent review (2007 – 2012)

(2013) Fabrizio Micheli et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Radioligands for the dopamine receptor subtypes

(2013) Olaf Prante et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Molecular signatures of G-protein-coupled receptors

(2013) A. J. Venkatakrishnan et al.   NATURE

Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders

(2013) Christian Heidbreder   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia

(2013) Gerhard Gross et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist

(2013) Jinbin Xu et al.   NEUROIMAGE

Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats

(2013) Rui Song et al.   NEUROPHARMACOLOGY

Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse Lewy body disease

(2013) J. Sun et al.   NEUROSCIENCE

Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys

(2013) Paul W. Czoty et al.   PSYCHOPHARMACOLOGY

The effects of the novel DA D3 receptor antagonist SR 21502 on cocaine reward, cocaine seeking and cocaine-induced locomotor activity in rats

(2013) E. Galaj et al.   PSYCHOPHARMACOLOGY

Pharmacologic Therapy for Primary Restless Legs Syndrome

(2013) Timothy J. Wilt et al.   JAMA Internal Medicine

Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response

(2013) A Bhathena et al.   Translational Psychiatry

Comparison of the Binding and Functional Properties of Two Structurally Different D2 Dopamine Receptor Subtype Selective Compounds

(2012) Robert R. Luedtke et al.   ACS Chemical Neuroscience

Blockade of dopamine D3receptors in the nucleus accumbens and central amygdala inhibits incubation of cocaine craving in rats

(2012) Zheng-Xiong Xi et al.   ADDICTION BIOLOGY

Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats

(2012) Gregory T. Collins et al.   BEHAVIOURAL PHARMACOLOGY

Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis

(2012) Amy Hauck Newman et al.   BIOCHEMICAL PHARMACOLOGY

High-affinity and selective dopamine D3 receptor full agonists

(2012) Jianyong Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

G protein-coupled receptor oligomerization and brain integration: Focus on adenosinergic transmission

(2012) Francisco Ciruela et al.   BRAIN RESEARCH

Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer

(2012) Sergi Ferre et al.   CNS & Neurological Disorders-Drug Targets

Functional Homomers and Heteromers of Dopamine D2Land D3Receptors Co-exist at the Cell Surface

(2012) Chantevy Pou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structure–Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization

(2012) Mark Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor

(2012) Amy Hauck Newman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Impulse Control and Related Disorders in Parkinson’s Disease

(2012) Daniel Weintraub et al.   Neurodegenerative Diseases

Mathematical modelling of [11C]-(+)-PHNO human competition studies

(2012) Graham E. Searle et al.   NEUROIMAGE

Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats

(2012) T.H.C. Cheung et al.   NEUROPHARMACOLOGY

D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat

(2012) Refugio Cruz-Trujillo et al.   NEUROPHARMACOLOGY

Occupancy of Brain Dopamine D3 Receptors and Drug Craving: A Translational Approach

(2012) Manolo Mugnaini et al.   NEUROPSYCHOPHARMACOLOGY

Multiple signaling routes involved in the regulation of adenylyl cyclase and extracellular regulated kinase by dopamine D2 and D3 receptors

(2012) Mingli Jin et al.   PHARMACOLOGICAL RESEARCH

Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain

(2012) Jianjun Sun et al.   PLoS One

Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization

(2012) D. Calebiro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The effects of the preferential dopamine D3 receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice

(2012) Onarae V. Rice et al.   SYNAPSE

YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice

(2011) Rui Song et al.   ADDICTION BIOLOGY

Reward, Addiction, Withdrawal to Nicotine

(2011) Mariella De Biasi et al.   Annual Review of Neuroscience

Increased Serum Brain-Derived Neurotrophic Factor Is Predictive of Cocaine Relapse Outcomes: A Prospective Study

(2011) Carrol D'Sa et al.   BIOLOGICAL PSYCHIATRY

Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor

(2011) Laurence J Miller et al.   BRITISH JOURNAL OF PHARMACOLOGY

Recent Advances in the Development of Dopamine D3 Receptor Antagonists: a Medicinal Chemistry Perspective

(2011) Fabrizio Micheli   ChemMedChem

Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors

(2011) Yoshihiro Tadori et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dopamine D3 receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats

(2011) Amanda E. Higley et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia

(2011) Laura Redden et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor Selectivity

(2011) Ashwini K. Banala et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pre-synaptic dopamine D3 receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways

(2011) Ginetta Collo et al.   JOURNAL OF NEUROCHEMISTRY

Ligand discovery from a dopamine D3 receptor homology model and crystal structure

(2011) Jens Carlsson et al.   Nature Chemical Biology

Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial

(2011) A. H. V. Schapira et al.   NEUROLOGY

Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex

(2011) David JG Watson et al.   NEUROPSYCHOPHARMACOLOGY

The Physiology, Signaling, and Pharmacology of Dopamine Receptors

(2011) J.-M. Beaulieu et al.   PHARMACOLOGICAL REVIEWS

Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists

(2011) Marco Orru et al.   PLoS One

Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo

(2011) Jean-Dominique Gallezot et al.   SYNAPSE

CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist

(2011) Jianyong Chen et al.   ACS Medicinal Chemistry Letters

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

(2010) Christian A. Heidbreder et al.   Annals of the New York Academy of Sciences

Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist

(2010) Graham Searle et al.   BIOLOGICAL PSYCHIATRY

Role of Pramipexole in the Management of Parkinsonʼs Disease

(2010) Angelo Antonini et al.   CNS DRUGS

Subtype Selectivity of Dopamine Receptor Ligands: Insights from Structure and Ligand-Based Methods

(2010) Qi Wang et al.   Journal of Chemical Information and Modeling

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson’s Disease

(2010) Balaram Ghosh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

(2010) B. Kiss et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors

(2010) E. Silvano et al.   MOLECULAR PHARMACOLOGY

A selective role for dopamine in stimulus–reward learning

(2010) Shelly B. Flagel et al.   NATURE

Time-resolved FRET between GPCR ligands reveals oligomers in native tissues

(2010) Laura Albizu et al.   Nature Chemical Biology

Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy

(2010) Andri C. Tziortzi et al.   NEUROIMAGE

Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats

(2010) Lindsay R. Riddle et al.   NEUROPHARMACOLOGY

Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes

(2010) N. J. Smith et al.   PHARMACOLOGICAL REVIEWS

Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery

(2010) T. Kenakin et al.   PHARMACOLOGICAL REVIEWS

Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist

(2010) E. Y. T. Chien et al.   SCIENCE

Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression

(2010) Neil M. Richtand et al.   SYNAPSE

Endogenous dopamine (DA) competes with the binding of a radiolabeled D3 receptor partial agonist in vivo: A positron emission tomography study

(2010) Robert H. Mach et al.   SYNAPSE

Mechanism-based medication development for the treatment of nicotine dependence

(2009) Zheng-xiong Xi et al.   ACTA PHARMACOLOGICA SINICA

Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist–antagonist binding modulation

(2009) Vicent Casadó et al.   BIOCHEMICAL PHARMACOLOGY

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors

(2009) Jean-Louis Peglion et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function

(2009) Graeme Milligan   BRITISH JOURNAL OF PHARMACOLOGY

Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance

(2009) Roberto Maggio et al.   CURRENT OPINION IN PHARMACOLOGY

Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function

(2009) Chiara Fiorentini et al.   CURRENT OPINION IN PHARMACOLOGY

The role of dimerisation in the cellular trafficking of G-protein-coupled receptors

(2009) Graeme Milligan   CURRENT OPINION IN PHARMACOLOGY

The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking

(2009) Maram A. T. M. Khaled et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor Antagonists∥⊥

(2009) Amy Hauck Newman et al.   JOURNAL OF MEDICINAL CHEMISTRY

1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D3Receptor Antagonists

(2009) Fabrizio Micheli et al.   JOURNAL OF MEDICINAL CHEMISTRY

The life of diatoms in the world's oceans

(2009) E. Virginia Armbrust   NATURE

Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation

(2009) Yang Han et al.   Nature Chemical Biology

Building a new conceptual framework for receptor heteromers

(2009) Sergi Ferré et al.   Nature Chemical Biology

Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance

(2009) Roberto Maggio et al.   PARKINSONISM & RELATED DISORDERS

GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers?

(2009) Vicent Casadó et al.   PHARMACOLOGY & THERAPEUTICS

The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys

(2009) Cindy Achat-Mendes et al.   PSYCHOPHARMACOLOGY

[3H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D3receptors. I. In vitro characterization

(2009) Jinbin Xu et al.   SYNAPSE

Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways

(2009) Michelle Taylor et al.   SYNAPSE

The apparent cooperativity of some GPCRs does not necessarily imply dimerization

(2009) Marc Chabre et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cell replacement therapy for Parkinson's disease

(2008) Ruwani Wijeyekoon et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence

(2008) Christian Heidbreder   CNS & Neurological Disorders-Drug Targets

Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders

(2008) Rodrigo Cunha et al.   CURRENT PHARMACEUTICAL DESIGN

Dopamine D2 receptors form higher order oligomers at physiological expression levels

(2008) Wen Guo et al.   EMBO JOURNAL

Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation

(2008) Ginetta Collo et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Adenosine A2Areceptors assemble into higher-order oligomers at the plasma membrane

(2008) Pierre-Alexandre Vidi et al.   FEBS LETTERS

Identification of Dopamine D1–D3Receptor Heteromers

(2008) Daniel Marcellino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Design, Synthesis, and Evaluation of Potent and Selective Ligands for the Dopamine 3 (D3) Receptor with a Novel in Vivo Behavioral Profile

(2008) Jianyong Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel D3 Selective Dopaminergics Incorporating Enyne Units as Nonaromatic Catechol Bioisosteres: Synthesis, Bioactivity, and Mutagenesis Studies

(2008) Miriam Dörfler et al.   JOURNAL OF MEDICINAL CHEMISTRY

Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization

(2008) C. Fiorentini et al.   MOLECULAR PHARMACOLOGY

The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease

(2008) Dieter Scheller et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15

(2008) Béla Kiss et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users

(2008) Paul S. Frankel et al.   NEUROPHARMACOLOGY

Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138

(2008) Mark J. Millan et al.   THERAPIE

Vesicular Neurotransmitter Transporters as Targets for Endogenous and Exogenous Toxic Substances

(2007) Farrukh A. Chaudhry et al.   Annual Review of Pharmacology and Toxicology

Further Structure–Activity Relationships Study of Hybrid 7-{[2-(4-Phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol Analogues: Identification of a High-Affinity D3-Preferring Agonist with Potent in Vivo Activity with Long Duration of Action

(2007) Swati Biswas et al.   JOURNAL OF MEDICINAL CHEMISTRY